Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Repare Therapeutics Inc.

Market Cap 112M 96.7M 89.05M 83.55M 157M 10.61B 159M 1.05B 411M 5.18B 421M 412M 17.96B P/E Ratio 2023
-3.28x
P/E Ratio 2024 -0.66x
Enterprise Value -38.78M -33.46M -30.81M -28.91M -54.25M -3.67B -54.84M -364M -142M -1.79B -146M -142M -6.22B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
6 months+23.83%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.37
Extreme 1.37
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.75
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 2026-01-27
Director TitleAgeSince
Director/Board Member - 2026-01-27
Date Insider Type Main position Quantity % Market Cap.
01-27
BVF Partners LP
TenderCompany 10,166,943 23.5846%
01-27Issuer sale

Chairman

7,500 0.0174%
01-27Issuer sale

Controller/Auditor

82,122 0.1905%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+80.64%-78.24% 114M
+0.96%+1.94%-12.97%-13.01% 43.03B
+4.02%+7.26%+294.33%+533.90% 32.71B
-1.69%-2.76%+13.70%-16.14% 30.29B
+1.41%-0.70%-0.53%+28.87% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.40%+6.10% - - 13.54B
+0.03%+2.92%+56.75%+114.15% 13.35B
-1.09%-2.37%+5.07%+5.25% 12.97B
+0.93%-0.70%+107.81%+81.19% 12.11B
Average +0.42%+0.74%+62.12%+75.34% 21.26B
Weighted average by Cap. +0.32%+0.82%+60.11%+102.41%

Financials

2023 2024
Net sales 51.13 44.12 40.63 38.12 71.54 4.84K 72.32 480.42 187.38 2.37K 191.87 187.79 8.2K 53.48 46.14 42.49 39.87 74.82 5.06K 75.63 502.45 195.97 2.47K 200.67 196.4 8.57K
Net income -93.8M -80.93M -74.52M -69.92M -131M -8.88B -133M -881M -344M -4.34B -352M -344M -15.03B -84.69M -73.07M -67.29M -63.13M -118M -8.02B -120M -796M -310M -3.92B -318M -311M -13.57B
Net Debt -220M -190M -175M -164M -308M -20.85B -311M -2.07B -807M -10.19B -826M -809M -35.3B -151M -130M -120M -112M -211M -14.29B -213M -1.42B -553M -6.98B -566M -554M -24.18B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!